965 related articles for article (PubMed ID: 9404440)
21. Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves' Disease.
Kim MJ; Cho SW; Kim YA; Choi HS; Park YJ; Park DJ; Cho BY
Endocrinol Metab (Seoul); 2022 Jun; 37(3):524-532. PubMed ID: 35709827
[TBL] [Abstract][Full Text] [Related]
22. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA
Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
[TBL] [Abstract][Full Text] [Related]
24. Radioiodine treatment of Graves' disease - dose/response analysis.
Cepková J; Horáček J; Vižďa J; Doležal J
Acta Medica (Hradec Kralove); 2014; 57(2):49-55. PubMed ID: 25257150
[TBL] [Abstract][Full Text] [Related]
25. Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period.
Kaplowitz PB; Jiang J; Vaidyanathan P
J Pediatr Endocrinol Metab; 2020 Mar; 33(3):383-389. PubMed ID: 31603857
[TBL] [Abstract][Full Text] [Related]
26. Radioactive Iodine Therapy of Graves' Disease in Patients Pretreated With Methimazole Without Radioiodine Uptake for Dose Estimation.
Mihailescu DV; Hoscheit C; Fogelfeld L
Endocr Pract; 2024 Apr; 30(4):333-339. PubMed ID: 38307459
[TBL] [Abstract][Full Text] [Related]
27. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease.
Bogazzi F; Bartalena L; Campomori A; Brogioni S; Traino C; De Martino F; Rossi G; Lippi F; Pinchera A; Martino E
J Clin Endocrinol Metab; 2002 Oct; 87(10):4490-5. PubMed ID: 12364424
[TBL] [Abstract][Full Text] [Related]
28. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism.
Imseis RE; Vanmiddlesworth L; Massie JD; Bush AJ; Vanmiddlesworth NR
J Clin Endocrinol Metab; 1998 Feb; 83(2):685-7. PubMed ID: 9467593
[TBL] [Abstract][Full Text] [Related]
29. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
El Refaei SM; Shawkat W
Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
[TBL] [Abstract][Full Text] [Related]
30. Radioiodine therapy for Graves' disease: case selection and restrictions recommended to patients in North America.
Wartofsky L
Thyroid; 1997 Apr; 7(2):213-6. PubMed ID: 9133687
[TBL] [Abstract][Full Text] [Related]
31. Influence of prior carbimazole on the outcome of radioiodine therapy in pediatric and adolescent Graves' disease.
Ballal S; Soundararajan R; Singh H; Garg A; Chopra S; Bal C
Nucl Med Commun; 2015 Jun; 36(6):566-72. PubMed ID: 25757198
[TBL] [Abstract][Full Text] [Related]
32. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
Glinoer D; de Nayer P; Bex M;
Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
[TBL] [Abstract][Full Text] [Related]
33. Thionamides alter the efficacy of radioiodine treatment in patients with Graves' disease.
Koroscil TM
South Med J; 1995 Aug; 88(8):831-6. PubMed ID: 7631208
[TBL] [Abstract][Full Text] [Related]
34. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study.
Andrade VA; Gross JL; Maia AL
J Clin Endocrinol Metab; 2001 Aug; 86(8):3488-93. PubMed ID: 11502768
[TBL] [Abstract][Full Text] [Related]
35. Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study.
Brito JP; Payne S; Singh Ospina N; Rodriguez-Gutierrez R; Maraka S; Sangaralingham LR; Iñiguez-Ariza NM; Montori VM; Stan MN
Thyroid; 2020 Mar; 30(3):357-364. PubMed ID: 31973681
[No Abstract] [Full Text] [Related]
36. Efficacy of radioactive iodine treatment of graves' hyperthyroidism using a single calculated
Wong KK; Shulkin BL; Gross MD; Avram AM
Clin Diabetes Endocrinol; 2018; 4():20. PubMed ID: 30505461
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis and treatment of Graves disease.
Streetman DD; Khanderia U
Ann Pharmacother; 2003; 37(7-8):1100-9. PubMed ID: 12841824
[TBL] [Abstract][Full Text] [Related]
38. Increased Risk of Radioiodine Treatment Failure Associated with Graves Disease Refractory to Methimazole.
Kwak JJ; Altoos R; Jensen A; Altoos B; McDermott MT
Endocr Pract; 2020 Nov; 26(11):1312-1319. PubMed ID: 33471662
[TBL] [Abstract][Full Text] [Related]
39. Influence of propylthiouracil and methimazole pre-treatment on the outcome of iodine-131 therapy in hyperthyroid patients with Graves' disease.
Shi GM; Xu Q; Zhu CY; Yang YL
J Int Med Res; 2009; 37(2):576-82. PubMed ID: 19383254
[TBL] [Abstract][Full Text] [Related]
40. Correlation between thyroid volume and humoral thyroid autoimmunity after radioiodine therapy in Graves' disease.
Sawicka N; Sowiński J
Endokrynol Pol; 2012; 63(1):10-3. PubMed ID: 22378091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
